Cytisinicline
Cytisinicline (also known as cytisine) is now a licensed prescription-only medication in the UK.
This short film summarises what cytisinicline offers and urges health and social care organisations to make it available to people who smoke. The film was part-funded by a grant provided by Consilient Health who had no influence or input into the content.
Consilient Health announced the availability of Cytisine (now known as Cytisinicline) in January 2024 and Viatris launched Belnifrem® in June 2025.
A recent update from NICE, which incorporates cytisinicline into their smoking cessation guidelines [NG209], is available
here.
The following resources can be found at the end of this page:
- Cytisinicline briefing
- Cytisinicline summary and dosing guide
- Cytisinicline Summary of Product Characteristics (SPC)
- Cytisinicline application: Our colleagues from Greater Manchester have made an application to their Medicines Management Board to get cytisinicline on their ICB formulary; they have kindly allowed us to include it here as a resource
- Belnifrem overview
We will continue to develop resources as we gain more experience and expertise in the use of cytisinicline.
